These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Ahrén B; Schmitz O Horm Metab Res; 2004; 36(11-12):867-76. PubMed ID: 15655721 [TBL] [Abstract][Full Text] [Related]
5. Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo. Green BD; Gault VA; Mooney MH; Irwin N; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP J Mol Endocrinol; 2003 Dec; 31(3):529-40. PubMed ID: 14664713 [TBL] [Abstract][Full Text] [Related]
6. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. Neumiller JJ J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361 [TBL] [Abstract][Full Text] [Related]
7. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors. Holst JJ Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141 [TBL] [Abstract][Full Text] [Related]
8. Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats. Sudre B; Broqua P; White RB; Ashworth D; Evans DM; Haigh R; Junien JL; Aubert ML Diabetes; 2002 May; 51(5):1461-9. PubMed ID: 11978643 [TBL] [Abstract][Full Text] [Related]
9. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system. Vergès B; Bonnard C; Renard E Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831 [TBL] [Abstract][Full Text] [Related]
10. GLP-1 for type 2 diabetes. Ahrén B Exp Cell Res; 2011 May; 317(9):1239-45. PubMed ID: 21237153 [TBL] [Abstract][Full Text] [Related]
11. Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors. Holst JJ Adv Exp Med Biol; 2003; 524():263-79. PubMed ID: 12675249 [TBL] [Abstract][Full Text] [Related]
14. The incretin system and its role in type 2 diabetes mellitus. Holst JJ; Vilsbøll T; Deacon CF Mol Cell Endocrinol; 2009 Jan; 297(1-2):127-36. PubMed ID: 18786605 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. Green BD; Irwin N; Duffy NA; Gault VA; O'harte FP; Flatt PR Eur J Pharmacol; 2006 Oct; 547(1-3):192-9. PubMed ID: 16945366 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Holst JJ; Deacon CF Diabetes; 1998 Nov; 47(11):1663-70. PubMed ID: 9792533 [TBL] [Abstract][Full Text] [Related]
17. Newly approved and promising antidiabetic agents. Combettes M; Kargar C Therapie; 2007; 62(4):293-310. PubMed ID: 17983555 [TBL] [Abstract][Full Text] [Related]
18. GLP-1 based therapy for type 2 diabetes. Arulmozhi DK; Portha B Eur J Pharm Sci; 2006 May; 28(1-2):96-108. PubMed ID: 16488579 [TBL] [Abstract][Full Text] [Related]
19. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus]. Escalada FJ Med Clin (Barc); 2014 Sep; 143 Suppl 2():2-7. PubMed ID: 25437458 [TBL] [Abstract][Full Text] [Related]
20. A novel GLP-1 analog, BPI3006, with potent DPP IV resistance and good glucoregulatory effect. Li C; Huan Y; Shen N; Ji L; Sun S; Liu S; Liu Q; Gao L; Tan F; Wang Y; Shen Z Biochem Biophys Res Commun; 2010 Oct; 400(4):563-8. PubMed ID: 20804731 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]